What are the recommended pharmacotherapies (pharmacological therapies) for obesity (excess body weight) management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most effective medications for weight loss, as recommended by the latest clinical practice guideline, are semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER, which should be used in addition to lifestyle interventions for adults with overweight and obesity. When considering medication for weight loss, it's essential to evaluate the patient's body mass index (BMI) and the presence of weight-related complications. According to the guideline published in Gastroenterology in 2022 1, pharmacotherapy is strongly recommended for adults with a BMI of 30 kg/m2 or 27 kg/m2 with weight-related complications who have an inadequate response to lifestyle interventions. The recommended medications, including semaglutide and liraglutide, are GLP-1 receptor agonists that have been shown to be effective in promoting weight loss. Phentermine-topiramate ER and naltrexone-bupropion ER are also suggested for long-term management of overweight and obesity. Key points to consider when prescribing these medications include:

  • Starting with a low dose and gradually increasing as needed and tolerated
  • Monitoring for potential side effects, such as nausea, constipation, and increased heart rate
  • Encouraging patients to make lifestyle changes, including a healthy diet and regular physical activity, to enhance the effectiveness of the medication
  • Regularly assessing the patient's progress and adjusting the treatment plan as needed. It's also important to note that orlistat is not recommended due to its limited efficacy and potential side effects, as stated in the guideline 1.

From the FDA Drug Label

Phentermine Hydrochloride, USP 15 mg and 30 mg is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m 2, or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).

The recommended medication for weight loss is phentermine. It is indicated for short-term use in patients with a body mass index (BMI) of 30 kg/m2 or higher, or 27 kg/m2 or higher with other risk factors. Key points to consider:

  • Indications: short-term adjunct in a weight reduction regimen
  • Patient selection: BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with other risk factors
  • Dosage: 15-30 mg daily, individualized to obtain an adequate response with the lowest effective dose 2

From the Research

Recommended Medications for Weight Loss

The following medications are recommended for weight loss:

  • Orlistat 3, 4, 5, 6
  • Phentermine/topiramate 3, 4, 5, 6
  • Naltrexone/bupropion 3, 4, 5, 7, 6
  • Liraglutide 3, 4, 5, 7, 6
  • Semaglutide 3, 4, 7
  • Setmelanotide 3 (approved for those with ultra-rare genetic diseases characterized by severe, early onset obesity)
  • Tirzepatide and cagrilintide/semaglutide combination 3 (showing promise for even greater weight loss efficacy in phase 3)

Efficacy of Medications

These medications have been shown to produce weight loss, with semaglutide producing an average of 15% weight loss at 1 year 3, 4. The efficacy of these medications can be enhanced when used in combination with lifestyle interventions such as diet and exercise 7, 6.

Considerations for Prescribing Medications

When prescribing medications for weight loss, clinicians should consider the patient's specific set of circumstances and comorbidities 4, 6. The benefits of losing fat mass may outweigh the potential side effects associated with these medications, particularly in patients at risk of complications from obesity 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drugs for Treating Obesity.

Handbook of experimental pharmacology, 2022

Research

Obesity Pharmacotherapy.

The Medical clinics of North America, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.